Antimicrobial
|
Organism
|
N
|
N (%) > ECOFF
|
MIC mg/l, % of isolates
|
ECOFFa
|
---|
Benzylpenicillin
| | | |
≤0.03
|
0.06
|
0.12
|
0.25
|
0.5
|
1
|
2
|
4
|
≥8
| | | | |
0.125
b
|
S. chromogenes
|
6
|
1 (16.7)
|
33.3
|
50.0
| | | |
16.7
| | | | | | | | |
S. epidermidis
|
27
|
20 (74.1)
|
18.5
|
3.7
|
3.7
|
11.1
|
7.4
|
18.5
|
7.4
|
22.2
|
7.4
| | | | | |
S. haemolyticus
|
5
|
2 (40.0)
|
20.0
|
40.0
| | | |
40.0
| | | | | | | | |
S. simulans
|
30
|
2 (6.6)
|
63.3
|
30.0
| | | |
3.3
|
3.3
| | | | | | | |
Oxacillin
| | | | | |
≤0.12
|
0.25
|
0.5
|
1
|
2
|
4
|
8
|
16
|
≥32
| | |
1.0
|
S. chromogenes
|
6
| | | |
16.7
|
16.7
|
66.7
| | | | | | | | | |
S. epidermidis
|
27
|
4 (14.8)
| | | |
3.7
|
66.7
|
14.8
| |
3.7
|
3.7
| |
7.4
| | | |
S. haemolyticus
|
5
| | | | | |
80.0
|
20.0
| | | | | | | | |
S. simulans
|
30
|
2 (6.6)
| | | |
6.7
|
36.7
|
50.0
|
3.3
|
3.3
| | | | | | |
Cephalothin
| | | | |
≤0.06
|
0.12
|
0.25
|
0.5
|
1
|
2
|
4
|
≥8
| | | | |
1.0
b
|
S. chromogenes
|
6
| | | |
50.0
|
50.0
| | | | | | | | | | |
S. epidermidis
|
27
| | |
3.7
|
40.7
|
37.0
|
11.1
|
7.4
| | | | | | | | |
S. haemolyticus
|
5
| | | |
20.0
|
40.0
|
40.0
| | | | | | | | | |
S. simulans
|
30
| | | |
6.7
|
70.0
|
23.3
| | | | | | | | | |
Streptomycin
| | | | | | | | | | |
≤4
|
8
|
16
|
32
|
≥64
| |
16.0
b
|
S. chromogenes
|
6
| | | | | | | | |
83.3
| |
16.7
| | | | |
S. epidermidis
|
27
|
2 (7.4)
| | | | | | | |
81.5
|
11.1
| |
3.7
|
3.7
| | |
S. haemolyticus
|
5
| | | | | | | | |
100.0
| | | | | | |
S. simulans
|
30
|
1 (3.3)
| | | | | | | |
73.3
|
20.0
|
3.3
| |
3.3
| | |
Neomycin
| | | | | | | | | | |
≤4
|
8
|
16
|
32
|
≥64
| |
1.0
b
|
S. chromogenes
|
6
| | | | | | | | |
100.0
| | | | | | |
S. epidermidis
|
27
| | | | | | | | |
96.3
| | |
3.7
| | | |
S. haemolyticus
|
5
| | | | | | | | |
100.0
| | | | | | |
S. simulans
|
30
| | | | | | | | |
100.0
| | | | | | |
Gentamicin
| | | | | | | |
≤0.5
|
1
|
2
|
4
|
8
|
≥16
| | | |
0.5
|
S. chromogenes
|
6
| | | | | |
100.0
| | | | | | | | | |
S. epidermidis
|
27
| | | | | |
100.0
| | | | | | | | | |
S. haemolyticus
|
5
| | | | | |
100.0
| | | | | | | | | |
S. simulans
|
30
|
1 (3.3)
| | | | |
96.7
|
3.3
| | | | | | | | |
Clindamycin
| | | | | | |
≤0.25
|
0.5
|
1
|
2
|
4
|
≥8
| | | | |
0.25
|
S. chromogenes
|
6
| | | | |
100.0
| | | | | | | | | | |
S. epidermidis
|
27
| | | | |
100.0
| | | | | | | | | | |
S. haemolyticus
|
5
| | | | |
100.0
| | | | | | | | | | |
S. simulans
|
30
|
3 (10.0)
| | | |
90.0
|
10.0
| | | | | | | | | |
Erythromycin
| | | | | | |
≤0.25
|
0.5
|
1
|
2
|
4
|
≥8
| | | | |
1.0
|
S. chromogenes
|
6
| | | | | |
83.3
|
16.7
| | | | | | | | |
S. epidermidis
|
27
| | | | |
25.9
|
70.4
|
3.7
| | | | | | | | |
S. haemolyticus
|
5
| | | | |
20.0
|
80.0
| | | | | | | | | |
S. simulans
|
30
| | | | |
10.0
|
86.7
|
3.3
| | | | | | | | |
Chloramphenicol
| | | | | | | | | |
≤2
|
4
|
8
|
16
|
≥32
| | |
16.0
|
S. chromogenes
|
6
| | | | | | | | |
33.3
|
66.7
| | | | | |
S. epidermidis
|
27
| | | | | | | | |
92.6
|
7.4
| | | | | |
S. haemolyticus
|
5
| | | | | | | | |
100.0
| | | | | | |
S. simulans
|
30
| | | | | | | | |
76.7
|
23.3
| | | | | |
Tetracycline
| | | | | | | |
≤0.5
|
1
|
2
|
4
|
8
|
16
|
32
|
64
|
≥128
|
1.0
|
S. chromogenes
|
6
| | | | | |
100.0
| | | | | | | | | |
S. epidermidis
|
27
|
7 (25.9)
| | | | |
66.7
|
7.4
|
18.5
| | | | |
7.4
| | |
S. haemolyticus
|
5
| | | | | |
100.0
| | | | | | | | | |
S. simulans
|
30
|
2 (6.7)
| | | | |
90.0
|
3.3
| | | |
6.7
| | | | |
Trimetoprim-sulfamethoxazole
| | | | | | | |
≤0.5/9.5
|
1/19
|
2/38
|
≥4/76
| | | | | |
0.5/9.5
|
S. chromogenes
|
6
| | | | | |
100.0
| | | | | | | | | |
S. epidermidis
|
27
|
2 (7.4)
| | | | |
92.6
| | |
7.4
| | | | | | |
S. haemolyticus
|
5
| | | | | |
100.0
| | | | | | | | | |
S. simulans
|
30
| | | | | |
100.0
| | | | | | | | | |
Cefoxitin
| | | | | |
≤0.12
|
0.25
|
0.5
|
1
|
2
|
4
|
8
|
16
|
≥32
| | |
4.0
b
|
S. chromogenes
|
6
| | | | | |
83.3
|
16.7
| | | | | | | | |
S. epidermidis
|
27
|
5 (18.5)
| | | | | |
3.7
|
55.6
|
22.2
|
7.4
|
3.7
|
7.4
| | | |
S. haemolyticus
|
5
| | | | | | | |
40.0
|
60.0
| | | | | | |
S. simulans
|
30
| | | | | |
3.3
| |
80.0
|
16.7
| | | | | | |
Kanamycin
| | | | | |
≤0.12
|
0.25
|
0.5
|
1
|
2
|
4
|
8
|
16
|
32
|
≥64
| |
8.0
b
|
S. chromogenes
|
6
| | | | | |
33.3
|
66.7
| | | | | | | | |
S. epidermidis
|
27
|
2 (7.4)
| | | | |
18.5
|
48.1
|
25.9
| | |
3.7
| |
3.7
| | |
S. haemolyticus
|
5
| | | | | |
80.0
|
20.0
| | | | | | | | |
S. simulans
|
30
| | | | | |
30.0
|
40.0
|
30.0
| | | | | | | |
Florphenicol
| | | | | | | | | |
≤2
|
4
|
8
|
≥16
| | | |
8.0
b
|
S. chromogenes
|
6
| | | | | | | |
50.0
|
50.0
| | | | | | |
S. epidermidis
|
27
| | | | | | | |
48.1
|
51.9
| | | | | | |
S. haemolyticus
|
5
| | | | | | | |
60.0
|
40.0
| | | | | | |
S. simulans
|
30
| | | | | | | |
10.0
|
86.7
|
3.3
| | | | | |
Trimetoprim
| | | | | | | |
≤0.5
|
1
|
2
|
4
|
8
|
16
|
32
|
≥64
| |
2.0
b
|
S. chromogenes
|
6
| | | | | | |
50.0
|
50
| | | | | | | |
S. epidermidis
|
27
|
4 (14.8)
| | | | |
11.1
|
44.4
|
29,6
| |
3.7
|
3.7
| |
7.4
| | |
S. haemolyticus
|
5
|
4 (80.0)
| | | | | | |
20.0
|
40.0
| |
40.0
| | | | |
S. simulans
|
30
|
29 (96.7)
| | | | | | |
3.3
|
6.7
|
36.7
|
50.0
|
3.3
| | | |
Ciprofloxacin
| | | | |
≤0.06
|
0.12
|
0.25
|
0.5
|
≥1
| | | | | | | |
1.0
|
S. chromogenes
|
6
| | | |
100.0
| | | | | | | | | | | |
S. epidermidis
|
27
| | | |
14.8
|
81.5
|
3.7
| | | | | | | | | |
S. haemolyticus
|
5
| | | | |
80.0
|
20.0
| | | | | | | | | |
S. simulans
|
30
| | | |
50.0
|
50.0
| | | | | | | | | | |
Fusidic acid
| | | | |
≤0.06
|
0.12
|
0.25
|
0.5
|
1
|
2
|
4
|
8
|
≥16
| | | |
0.5
|
S. chromogenes
|
6
|
1 (16.7)
| | | |
66.7
|
16.7
|
16.7
| | | | | | | | |
S. epidermidis
|
27
|
10 (37.0)
| | | |
3.7
|
59.3
|
25.9
| | |
3.7
|
7.4
| | | | |
S. haemolyticus
|
5
| | | | | |
100.0
| | | | | | | | | |
S. simulans
|
30
|
10 (33.3)
| | | |
6.7
|
60.0
|
33.3
| | | | | | | | |
- In this dataset, samples were collected in the Finnish veterinary antimicrobial resistance monitoring program 2010-2012 [18] and they originated from quarters with mastitis
-
aCurrent (March 2015) EUCAST epidemiological cut-off (ECOFF) values (mg/l) for CNS were used to define resistant isolates. If ECOFF for CNS was not available, the value for S. aureus was used. For virginiamycin, ECOFF for S. intermedius was used
-
bECOFF for S. aureus